Introduction
============

Colorectal cancer (CRC) is a frequent malignancy, the second most common cancer in women and the third most common in men, with an estimated 1.4 million cases and 693,900 deaths in 2012^[@B1])^. Although the surgical procedures and chemotherapy for CRC have been developed in recent years^[@B2]-[@B4])^, some patients relapsed after curative resection, affecting the survival percentage. At present, the tumor-node-metastasis (TNM) staging system of the International Union Against Cancer (Union for International Cancer Control, UICC) is most commonly used to predict the prognosis for CRC of all stages^[@B5])^. However, there are differences in prognosis among the same TNM stages^[@B6])^. Therefore, it is necessary to develop a more accurate prognostic prediction model for individual outcomes, leading to personalized therapy. Recently, it has been considered that the progression and prognosis of cancer correlate with the inflammatory^[@B7])^ and nutritional status of patients^[@B8],[@B9])^. The prognostic nutritional index (PNI), calculated by serum albumin level and total lymphocyte count (TLC), has been reported to reflect the nutritional and immune condition of patients^[@B10],[@B11])^. PNI has also been reported to correlate with postoperative complications^[@B12],[@B13])^ and is considered as a prognostic predictor for various cancers^[@B13],[@B14])^, such as hepatocellular carcinoma^[@B15])^, pancreatic carcinoma^[@B16])^, gastric carcinoma^[@B17])^, and CRC^[@B18]-[@B20])^. While several studies suggested that the PNI is related to the prognosis of CRC, the optimal cut-off values for the PNI to determine prognosis remain to be elucidated. In this study, we examined the clinicopathological risk factors including the PNI for recurrence and mortality in patients with CRC. The optimal cut-off values of the PNI for predicting prognosis were investigated. Moreover, we constructed a novel prediction model for disease-free survival (DFS) and overall survival (OS) using the PNI in patients with CRC. Developing this tool can provide beneficial information regarding selecting a personalized treatment for each patient.

Methods
=======

Patients and data sets
----------------------

240 patients with CRC who underwent curative resection for primary and metastatic lesions at Osaka University Hospital from October 2011 to December 2012 were enrolled in this study retrospectively. Patients with no detailed preoperative laboratory data and pathological findings were excluded. Patients who underwent transanal endoscopic microsurgeries were also excluded because of the lack of pathological findings. Finally, 149 patients were analyzed in this study ([Figure 1](#g001){ref-type="fig"}). The median follow-up was 59 months (range: 1-73 months). Data on the age, sex, body mass index (BMI), American Society of Anesthesiologists Physical Status (ASA-PS), serum level of albumin, TLC, white blood cells (WBCs), C-reactive protein (CRP), carcinoembryonic antigen (CEA), primary tumor location (colon or rectum), distant metastases, and pathological findings (e.g., histological grade, tumor invasion, lymph node metastasis, lymphatic invasion, and venous invasion) were retrieved from the patients\' medical records. The clinicopathological factors were classified according to the seventh edition of the UICC TNM classification^[@B5])^. Preoperative blood samples were obtained within a month before operation. The PNI was calculated as follows: 10 × serum albumin level (g/dL) + 0.005 × TLC (/mm^3^)^[@B10])^. After surgery, all patients were followed up regularly, with blood examinations assessing CEA and carbohydrate antigen 19-9 and further screening by computed tomography every 3-6 months and colonoscopy every 1-2 years following the Japanese guidelines^[@B21])^. This study was approved by the Institutional Review Board of Osaka University.

![Flowchart of the patients included in this study.](2432-3853-3-0106-g001){#g001}

Statistical analysis
--------------------

Differences between the clinicopathological factors and the classified PNI groups were analyzed using the chi-squared test and Mann-Whitney *U* test. Univariate and multivariate analyses were performed using a Cox proportional hazards regression model to identify the independent prognostic factors for DFS and OS. Two-sided *P* \< 0.05 was considered to denote statistical significance. Kaplan-Meier survival curves were plotted and compared with the generalized log-rank test. The predictive performance of the nomogram was calculated by the concordance index (c-index)^[@B22])^. All statistical analyses were performed using JMP^Ⓡ^ software version 14 (SAS Institute Inc., Cary, NC, USA). The nomogram was structured using R 3.1.3 (CRAN; the R Foundation for Statistical Computing, Vienna, Austria)^[@B23])^.

Results
=======

Patient characteristics
-----------------------

The characteristics of all 149 patients are listed in [Table 1](#t001){ref-type="table"}. The median age was 64 years (range: 26-87 years). Seven patients (4.7%) were at stage IV. In the stage IV cases, which included liver metastasis (five cases), peritoneal dissemination (one case), and lymph node metastasis of extra region (one case), concurrent surgically curative resection of both primary and metastatic lesions was performed. There were 25 patients (16.8%) with recurrences after surgery, 8 with lung, 7 with liver, 5 with local site, 4 with lymph node, and 1 with ovary metastases.

###### 

The Characteristics of the 149 Patients with CRC.

  Variables                     PNI                    
  ----------------------------- ---------------------- --------------------
  Age (years) \*                63 (26-87)             68 (42-85)
  Sex                                                  
  Male/female                   50/32                  43/24
  BMI (kg/m^2^) \*              22.2 (8.7-32.0)        21.8 (14.6-27.3)
  ASA-PS                                               
  1/2/3/4-6                     42/37/3/0              23/35/9/0
  Alb (g/dL) \*                 4.1 (3.6-4.9)          3.5 (1.9-4.2)
  TLC (/μL) \*                  1,645 (881-3,734)      1,222 (463-3,018)
  WBCs (/μL) \*                 5,415 (2,650-13,290)   5,660 (860-13,700)
  CRP (mg/dL) \*                0.06 (0.04-0.91)       0.32 (0.04-15.31)
  Preoperative CEA (ng/mL) \*   3 (1-19)               4 (0.1-174)
  Tumor location                                       
  Colon/rectum                  50/32                  45/22
  Degree of differentiation                            
  tub1/tub2/por/pap/muc         38/37/2/2/3            35/26/3/0/3
  Depth of tumor invasion                              
  Tis/T1/T2/T3/T4               4/33/17/27/1           5/9/11/32/10
  Lymph node metastasis                                
  N0/N1/N2                      60/15/7                46/17/4
  Venous invasion                                      
  Present/absent                16/66                  16/51
  Lymphatic vessel invasion                            
  Present/absent                37/45                  42/25
  Distant metastasis                                   
  Present/absent                2/80                   5/62
  TNM stage                                            
  0/I/II/III/IV                 4/43/12/21/2           5/17/21/19/5

CRC: colorectal cancer; PNI: prognostic nutritional index; BMI: body mass index; ASA-PS: American Society of Anesthesiologists Physical Status; Alb: albumin; TLC: total lymphocyte count; WBC: white blood cell; CRP: C-reactive protein; CEA: carcinoembryonic antigen; tub1: well-differentiated adenocarcinoma; tub2: moderately differentiated adenocarcinoma; por: poorly differentiated adenocarcinoma; pap: papillary adenocarcinoma; muc: mucinous adenocarcinoma; TNM: tumor node metastasis. \*Median (range).

Cut-off value of PNI
--------------------

The median preoperative PNI was 46.7 (range: 23.6-63.0), and the PNI distribution was normal. According to the median PNI, we set 46 as the cut-off value for PNI and classified the patients into a high-PNI (≥46) group (82 patients, 55.0%) and a low-PNI (\<46) group (67 patients, 45.0%). The relationship between the PNI status and clinicopathological factors in the patients is shown in [Table 2](#t002){ref-type="table"}. Between the high- and low-PNI groups, there were no significant differences in the sex, BMI, WBCs, tumor location, degree of differentiation, lymph node metastasis, venous invasion, and distant metastasis.

###### 

The Relationship between the PNI Status and Clinicopathological Factors in 149 Patients with CRC.

  Variables                   Number (%)   PNI                     
  --------------------------- ------------ ----------- ----------- -----------
  PNI                         149 (100)    82 (55.0)   67 (45.0)   
  Age (years)                                                      \<0.001\*
  Age \< 65                   77 (51.7)    53 (68.8)   24 (31.2)   
  Age ≥ 65                    72 (48.3)    29 (40.3)   43 (59.7)   
  Sex                                                              0.688
  Male                        93 (62.4)    50 (53.8)   43 (46.2)   
  Female                      56 (37.6)    32 (57.1)   24 (42.9)   
  BMI (kg/m^2^)                                                    0.369
  BMI ≥ 22                    75 (50.3)    44 (58.7)   31 (41.3)   
  BMI \< 22                   74 (49.7)    38 (51.3)   36 (48.7)   
  ASA-PS                                                           0.028\*
  1, 2                        137 (91.9)   79 (57.7)   58 (42.3)   
  3-6                         12 (8.1)     3 (25.0)    9 (75.0)    
  Alb (g/dL)                                                       \<0.001\*
  Alb ≥ 3.5                   116 (77.9)   82 (70.7)   34 (29.3)   
  Alb \< 3.5                  33 (22.1)    0 (0)       33 (100)    
  TLC (/μL)                                                        \<0.001\*
  TLC ≥ 1,500                 66 (44.3)    50 (75.8)   16 (24.2)   
  TLC \< 1,500                83 (55.7)    32 (38.6)   51 (61.4)   
  WBCs (/μL)                                                       0.076
  WBCs ≥ 10,000               8 (5.4)      2 (25.0)    6 (75.0)    
  WBCs \< 10,000              141 (94.6)   80 (56.7)   61 (43.3)   
  CRP (mg/dL)                                                      \<0.001\*
  CRP ≥ 1                     18 (12.1)    0 (0)       18 (100)    
  CRP \< 1                    131 (87.9)   82 (62.6)   49 (37.4)   
  Preoperative CEA (ng/mL)                                         \<0.001\*
  CEA ≥ 5                     49 (32.9)    18 (36.7)   31 (63.3)   
  CEA \< 5                    100 (67.1)   64 (64.0)   36 (36.0)   
  Tumor location                                                   0.434
  Colon                       95 (63.8)    50 (52.6)   45 (47.4)   
  Rectum                      54 (36.2)    32 (59.3)   22 (40.7)   
  Degree of differentiation                                        0.928
  tub1, tub2                  136 (91.3)   75 (55.2)   61 (44.8)   
  por, pap, muc               13 (8.7)     7 (53.9)    6 (46.1)    
  Depth of tumor invasion                                          \<0.001\*
  Tis, T1, T2                 79 (53.0)    54 (68.3)   25 (31.7)   
  T3, T4                      70 (47.0)    28 (40.0)   42 (60.0)   
  Lymph node metastasis                                            0.546
  N0                          106 (71.1)   60 (56.6)   46 (43.4)   
  N1, N2                      43 (28.9)    22 (51.2)   21 (48.8)   
  Venous invasion                                                  0.518
  Present                     32 (21.5)    16 (50.0)   16 (50.0)   
  Absent                      117 (78.5)   66 (56.4)   51 (43.6)   
  Lymphatic vessel invasion                                        0.033\*
  Present                     79 (53.0)    37 (46.8)   42 (53.2)   
  Absent                      70 (47.0)    45 (64.3)   25 (35.7)   
  Distant metastasis                                               0.149
  Present                     7 (4.7)      2 (28.6)    5 (71.4)    
  Absent                      142 (95.3)   80 (56.3)   62 (43.7)   
  TNM stage                                                        0.003\*
  0-I                         69 (46.3)    47 (68.1)   22 (31.9)   
  II-IV                       80 (53.7)    35 (43.8)   45 (56.2)   

CRC: colorectal cancer; PNI: prognostic nutritional index; BMI: body mass index; ASA-PS: American Society of Anesthesiologists Physical Status; Alb: albumin; TLC: total lymphocyte count; WBC: white blood cell; CRP: C-reactive protein; CEA: carcinoembryonic antigen; tub1: well-differentiated adenocarcinoma; tub2: moderately differentiated adenocarcinoma; por: poorly differentiated adenocarcinoma; pap: papillary adenocarcinoma; muc: mucinous adenocarcinoma; TNM: tumor node metastasis. Values with an asterisk indicate *P*-values of \<0.05.

Survival analysis according to the PNI groups
---------------------------------------------

The median patient follow-up time was 59 months. The DFS rate was significantly worse in the low-PNI group compared to the high-PNI group (*P* = 0.006) ([Figure 2](#g002){ref-type="fig"}). The five-year DFS rate was 89.8% in the high-PNI group and 73.2% in the low-PNI group. The OS rate was also significantly worse in the low-PNI group compared to the high-PNI group (*P* \< 0.001) ([Figure 3](#g003){ref-type="fig"}). The five-year OS rate was 92.4% in the high-PNI group and 68.1% in the low-PNI group.

![DFS curves according to the PNI. The Kaplan-Meier plots show the DFS based on the high-PNI (≥46) and the low-PNI (\<46) group in 149 patients with CRC after curative resection. The DFS rate was significantly worse in the low-PNI group (*P* = 0.006).](2432-3853-3-0106-g002){#g002}

![OS curves according to the PNI. The Kaplan-Meier plots show the OS based on the high-PNI (≥46) and the low-PNI (\<46) group in 149 patients with CRC after curative resection. The OS rate was significantly worse in the low-PNI group (*P* \< 0.001).](2432-3853-3-0106-g003){#g003}

Risk factors for recurrence and mortality
-----------------------------------------

Univariate and multivariate analyses of clinicopathological factors for DFS are shown in [Table 3](#t003){ref-type="table"}. According to the univariate analysis, a high preoperative serum CEA level (*P* = 0.010), tumor location at the rectum (*P* = 0.023), depth of tumor invasion (*P* = 0.002), lymph node metastasis (*P* = 0.001), venous invasion (*P* \< 0.001), lymphatic vessel invasion (*P* = 0.003), distant metastasis (*P* \< 0.001), and low PNI (*P* = 0.009) were significantly correlated with DFS. Furthermore, the multivariate analysis showed that tumor location at the rectum (*P* = 0.028), venous invasion (*P* = 0.009), and low PNI (*P* = 0.008) were independent recurrence risk factors. The univariate and multivariate analyses of clinicopathological factors for OS are shown in [Table 4](#t004){ref-type="table"}. According to the univariate analysis, advanced age (*P* = 0.045), preoperative low serum albumin level (*P* \< 0.001), high CRP (P = 0.030), high preoperative CEA (*P* = 0.012), depth of tumor invasion (*P* = 0.007), venous invasion (*P* = 0.005), lymphatic vessel invasion (*P* = 0.022), distant metastasis (*P* = 0.026), and low PNI (*P* \< 0.001) were significantly correlated with OS. Furthermore, the multivariate analysis showed that advanced age (*P* = 0.022), venous invasion (*P* = 0.027), and low PNI (*P* = 0.029) were independent prognostic risk factors. Moreover, we also performed univariate and multivariate analyses including the TNM stage instead of T, N, and M factors for DFS and OS ([Supplementary Tables S1 and S2](#s001){ref-type="supplementary-material"}). The multivariate analysis showed that tumor location at the rectum (*P* = 0.010), venous invasion (*P* = 0.013), advanced TNM stage (*P* = 0.012), and low PNI (*P* = 0.038) were independent recurrence risk factors and that advanced age (*P* = 0.040), venous invasion (*P* = 0.018), and low PNI (*P* = 0.013) were independent prognostic risk factors.

###### 

Univariate and Multivariate Analyses of DFS in Patients with CRC.

  Variables                                              Univariate                  Multivariate                             
  ------------------------------------------------------ ------------ -------------- -------------- -- ------- -------------- ---------
  Age (\<65/≥65 years)                                   2.227        0.961-5.759    0.062                                    
  Sex (male/female)                                      1.008        0.449-2.401    0.984                                    
  BMI (\<25/≥25)                                         1.677        0.578-7.104    0.372                                    
  ASA-PS (\<3/≥3)                                        1.363        0.287-24.389   0.750                                    
  Alb (\<3.5/≥3.5)                                       1.493        0.541-3.563    0.412                                    
  TLC (\<1,500/≥1,500)                                   1.744        0.767-4.303    0.199                                    
  WBCs (≥10,000/\<10,000)                                1.033        0.058-4.906    0.975                                    
  CRP (≥1/\<1)                                           1.376        0.325-3.993    0.620                                    
  Preoperative CEA (≥5/\<5)                              2.865        1.281-6.528    0.010\*           1.393   0.564-3.554    0.474
  Tumor location (rectum/colon)                          2.557        1.144-5.933    0.023\*           2.591   1.111-6.256    0.028\*
  Degree of differentiation (por, pap, muc/tub1, tub2)   2.097        0.610-5.543    0.214                                    
  Depth of tumor invasion (T3, T4/Tis, T1, T2)           4.178        1.750-11.529   0.002\*           1.096   0.296-3.904    0.888
  Lymph node metastasis (present/absent)                 3.951        1.765-9.177    0.001\*           2.550   0.955-7.640    0.062
  Venous invasion (present/absent)                       6.850        3.053-15.948   \<0.001\*         3.714   1.384-11.030   0.009\*
  Lymphatic vessel invasion (present/absent)             5.000        1.890-17.192   0.003\*           1.174   0.282-5.198    0.825
  Distant metastasis (present/absent)                    7.797        2.555-19.753   \<0.001\*         3.029   0.921-8.747    0.067
  PNI (\<46/≥46)                                         2.972        1.306-7.335    0.009\*           3.446   1.376-9.290    0.008\*

CRC: colorectal cancer; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; BMI: body mass index; ASA-PS: American Society of Anesthesiologists Physical Status; Alb: albumin; TLC: total lymphocyte count; WBC: white blood cell; CRP: C-reactive protein; CEA: carcinoembryonic antigen; por: poorly differentiated adenocarcinoma; pap: papillary adenocarcinoma; muc: mucinous adenocarcinoma; tub1: well-differentiated adenocarcinoma; tub2: moderately differentiated adenocarcinoma; PNI: prognostic nutritional index. Values with an asterisk indicate *P*-values of \<0.05.

###### 

Univariate and Multivariate Analyses of OS in Patients with CRC.

  Variables                                              Univariate                  Multivariate                            
  ------------------------------------------------------ ------------ -------------- -------------- -- ------- ------------- ---------
  Age (≥65/\<65 years)                                   2.232        1.017-5.242    0.045\*           2.969   1.168-8.290   0.022\*
  Sex (male/female)                                      1.453        0.652-3.544    0.369                                   
  BMI (\<25/≥25)                                         3.034        0.900-18.882   0.078                                   
  ASA-PS (≥3/\<3)                                        3.283        0.959-8.599    0.057                                   
  Alb (\<3.5/≥3.5)                                       5.775        2.661-12.726   \<0.001\*                               
  TLC (\<1,500/≥1,500)                                   1.309        0.601-2.991    0.502                                   
  WBCs (≥10,000/\<10,000)                                3.770        0.891-10.895   0.068                                   
  CRP (≥1/\<1)                                           3.108        1.134-7.321    0.030\*           1.215   0.400-3.285   0.716
  Preoperative CEA (≥5/\<5)                              2.697        1.243-5.943    0.012\*           1.164   0.461-2.976   0.749
  Tumor location (rectum/colon)                          1.459        0.663-3.161    0.340                                   
  Degree of differentiation (por, pap, muc/tub1, tub2)   2.152        0.629-5.633    0.198                                   
  Depth of tumor invasion (T3, T4/Tis, T1, T2)           2.970        1.333-7.244    0.007\*           1.242   0.400-3.863   0.706
  Lymph node metastasis (present/absent)                 1.422        0.606-3.120    0.403                                   
  Venous invasion (present/absent)                       3.249        1.451-7.054    0.005\*           3.002   1.136-8.150   0.027\*
  Lymphatic vessel invasion (present/absent)             2.609        1.146-6.684    0.022\*           1.334   0.483-3.963   0.585
  Distant metastasis (present/absent)                    4.173        1.218-10.945   0.026\*           2.861   0.723-9.502   0.125
  PNI (\<46/≥46)                                         4.670        1.988-12.776   \<0.001\*         2.889   1.109-8.422   0.029\*

CRC: colorectal cancer; OS: overall survival; HR: hazard ratio; CI: confidence interval; BMI: body mass index; ASA-PS: American Society of Anesthesiologists Physical Status; Alb: albumin; TLC: total lymphocyte count; WBC: white blood cell; CRP: C-reactive protein; CEA: carcinoembryonic antigen; por: poorly differentiated adenocarcinoma; pap: papillary adenocarcinoma; muc: mucinous adenocarcinoma; tub1: well-differentiated adenocarcinoma; tub2: moderately differentiated adenocarcinoma; PNI: prognostic nutritional index. Values with an asterisk indicate *P*-values of \<0.05.

Nomograms to predict prognosis
------------------------------

Nomograms to predict DFS and OS for patients with CRC who underwent curative surgery including stage IV were constructed. Since the TNM stage is the combination of primary tumor (T), regional lymph nodes (N), and distant metastasis (M), we developed nomograms using each independent clinicopathological risk factor shown in [Table 3](#t003){ref-type="table"}, [4](#t004){ref-type="table"}. Preoperative PNI, tumor location, and venous invasion were included in the nomogram to predict the DFS ([Figure 4](#g004){ref-type="fig"}). Preoperative PNI, age, and venous invasion were included in the nomogram to predict the OS ([Figure 5](#g005){ref-type="fig"}). The concordance index (c-index) of the nomogram was 0.828 for DFS and 0.756 for OS.

![Nomogram to predict DFS for CRC after curative surgical resection. The model was constructed using the Cox regression model. The clinicopathological factors used were the PNI, tumor location, and venous invasion. The prediction model can provide the probabilities of one-year, three-year, and five-year DFS after curative resection for individual patients by comparing the sum of the points identified on the points scale with the prediction scale.](2432-3853-3-0106-g004){#g004}

![Nomogram to predict OS for CRC after curative surgical resection. The model was constructed using the Cox regression model. The clinicopathological factors used were the PNI, age, and venous invasion. The prediction model can provide the probabilities of one-year, three-year, and five-year OS after curative resection for individual patients by comparing the sum of the points identified on the points scale with the prediction scale.](2432-3853-3-0106-g005){#g005}

Discussion
==========

About 20-45% of patients with CRC who underwent curative resection had recurrence^[@B24])^, and one-third of the patients died within 5 years after surgery^[@B25])^. It is important to prevent relapse in patients with CRC, even if they underwent curative resection. Recently, preoperative immune nutritional status has been considered to be an indicator of prognosis for patients with CRC. Various methods such as PNI, Glasgow Prognostic Score^[@B26])^, subjective global assessment^[@B27])^, and controlling nutritional status^[@B28])^ have been reported to evaluate the immune nutritional status. In this study, the Kaplan-Meier survival analysis showed that the PNI was significantly associated with prognosis in CRC. It was also revealed that low PNI, tumor location (rectum), and venous invasion were independent risk factors for DFS and that low PNI, advanced age, and venous invasion were independent risk factors for OS. In addition, we examined the relationship between the PNI and TNM stage ([Supplementary Figure. S1](#s001){ref-type="supplementary-material"}). Even though the PNI tended to be low as the TNM stage went up, no dominant correlation among them was found. Therefore, we considered that the PNI was an independent prognostic factor that did not depend on the TNM stage. We also examined the survival analysis of DFS and OS according to the TNM stage. The DFS rate did not exhibit a significant difference in all stages ([Supplementary Figure. S2](#s001){ref-type="supplementary-material"}). The OS rate was significantly worse in the low-PNI group compared with the high-PNI group in stage I and II patients ([Supplementary Figure. S3](#s001){ref-type="supplementary-material"}). However, the number of patients was too small to analyze every stage.

It was previously reported that serum albumin level and number of lymphocytes are associated with the prognosis of cancer^[@B29]-[@B31])^. Lymphocytes are considered to be essential for the elimination of cancer cells^[@B32])^, and malnutrition^[@B33],[@B34])^ and low number of lymphocytes^[@B31],[@B35])^ have been reported to correlate with an immunosuppressed condition. Inadequate antitumor immunological reaction was caused by the patient\'s immunosuppressed condition^[@B31],[@B35])^, which led to the establishment of a favorable microenvironment for recurrence due to interplay among soluble factors such as cytokines, chemokines, surface receptors and adhesion molecules^[@B36])^. However, the mechanism still remains to be elucidated.

Several cut-off values of PNI were reported according to the many situations. Various PNI values are used for each purpose. In patients with terminal cancer at 42 days before death, the value of 30 was reported to associate with survival time^[@B37])^. The value of 45 was used to predict the postoperative complications for patients with CRC^[@B13])^, and the value of 45-50 has been reported to be associated with recurrence and mortality in patients with CRC^[@B38]-[@B40])^. The cut-off value was also 46 in our study. Our method guaranteed satisfactory accuracy as shown in the Kaplan-Meier survival analysis with *P*-value and the nomograms with c-index.

In order to identify patients with poor survival, we developed novel and reliable personalized prognostic models using the PNI value, leading to the improvement of the strategies for cancer treatment. A nomogram is constructed by combining multiple prognostic variables. It provides more accurate prognostic prediction for individual patients than the classification by a single risk factor and might support the TNM staging system. Useful nomograms have been reported to predict survival for CRC previously. However, there was only one report of the nomogram using PNI, and it was for a patient with non-metastatic CRC to predict their survival^[@B41])^. Our study included stage IV patients after curative resection, so this is the first report of nomograms for patients with CRC at all stages. These models will contribute to identifying patients at a high risk of CRC who require careful follow-up and/or postoperative treatment even after curative resection.

There are some limitations in this study. First, this study was retrospective and had a single-center design. Second, we evaluated only a small number of patients. Therefore, a large number of prospective studies should be performed to examine the truly important risk factors and construct better predictive models. Third, we did not evaluate whether the improvement of the preoperative nutritional status led to a better prognosis. Some reports suggested that the enhanced recovery after the surgical protocol was associated with improved five-year cancer-specific survival^[@B42])^ and was less likely to develop postoperative complications^[@B43])^. To clarify the relationship between preoperative PNI and the prognosis, it will be necessary to improve preoperative nutritional status and compare the outcomes.

In conclusion, low PNI was related to recurrence and mortality in patients with CRC who underwent curative surgical resection. We developed novel prognostic prediction models for patients with CRC using the PNI. These models may provide more accurate individual prognostic outcomes and help personalized treatments.
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**Supplementary Table S1.**Univariate and multivariate analyses of DFS including the TNM stage in patients with CRC.

**Supplementary Table S2.**Univariate and multivariate analyses of OS including the TNM stage in patients with CRC.

**Supplementary Figure S1.**Relationship between the PNI and TNM stage.

**Supplementary Figure S2.**DFS curves according to the TNM stage by the PNI.

**Supplementary Figure S3.**OS curves according to the TNM stage by the PNI.
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